Acquisition Channels & SEO, with a competitive benchmark.

Ambiki has a large content footprint pointed at the wrong end of the funnel. A full crawl returns 4,222 URLs, but roughly two-thirds of them are free clinical tools for practitioners (activity lists, goal banks, resources), not buyer-intent pages. The result is a brand that clinicians can stumble into for free tools, and a business that is nearly invisible on the commercial keywords where EMR purchasesstart. On "best EMR for speech therapy 2026" and "Fusion alternative," Ambiki doesn’t rank on its own terms: third-party listicles (led by SPRY) and review aggregators (Capterra, GetApp, Software Advice) own those SERPs, and they slot Ambiki into a niche ("school-based/IEP") rather than the recommended pick.

The scale gap with the incumbent is stark and worth stating plainly: Ensora/Fusion reports 200,000+ providers and 28,000+ practices; Ambiki shows 311 LinkedIn followers and 14 Capterra reviews. Ambiki is not losing a demand-gen race by a little; it hasn’t really entered it. That’s not a criticism of effort (the free-tools engine is real and differentiated); it’s a diagnosis of aim. The content engine builds clinician affection; it does not build buyer pipeline. Those are different jobs, and only one of them shows up in the June 5 model’s "marketing-sourced pipeline" line.

Roughly 66% of indexed pages (activity-lists + goals + resources ≈ 2,780) are free clinical tools for practitioners. Buyer-facing commercial pages (product, pricing, comparison) are a rounding error by comparison. This is a deliberate, genuinely differentiated freemium-content strategy: give SLPs/OTs free, high-quality tools, earn brand affinity, convert a slice to the EMR. The @ambikitoolsInstagram handle and the "Therapy tools" product line are the same thesis. It’s a moat competitors can’t cheaply copy.

But it answers the wrong question for pipeline. A clinician searching "free articulation activities" is not a buyer evaluating an EMR merger for eight providers, the exact buyer in the secret shop. The content engine fills the top of a clinician-affinity funnel, not a purchasefunnel, and the two only overlap at the edges. This is the concrete, page-level version of the June 1 memo’s worry that Ambiki’s organic presence isn’t "metabolized into demand."

The category-education line is the sharpest: across the terms describing how buyers research the problem, Ambiki ranks on exactly one. And the competitor-alternative split matters: Ambiki built"Ambiki vs X" pages and ranks #1 on several, but it’s absent on the generic "[competitor] alternative" searches, so it captures people already comparing Ambiki, and misses everyone looking to leave a competitor.

Who owns those SERPs instead (from the outranked_by column) is the surprise, and it reframes the competitive threat:

• "best EMR for speech therapy" → #1 TheraPlatform, #3 ClinicNote, #5 Reddit.
• "speech therapy EMR software" → #1 TheraPlatform, #2 ClinicNote.
• "EMR for SLP private practice" → #1 ClinicNote, #3–4 Reddit, #6 TheraPlatform.
• "Fusion Web Clinic alternative"→ #1 Fusion’s own page, #3 ClinicNote: Ambiki, a genuinely strong Fusion alternative on price and fit, doesn’t appear.
• "TheraPlatform alternative" → TheraPlatform occupies #1, #3, and #4; it fully owns its own defensive SERP.
• "Ambiki vs Fusion" → #1 a Reddit thread, #2 Fusion, #3 ClinicNote: Ambiki is only #4 on its own comparison term, beaten by a forum, the incumbent, and a challenger.
• Reddit ranks on the front page across many buyer terms (and #1 on "AI scribe for speech therapy"); community/word-of-mouth is literally a top organic result, and the June 1 memo already flagged Ambiki’s absence from r/slp.

Every one of Ambiki’s five genuine non-branded ranks is a speech term. In OT, PT, ABA, and feeding (disciplines it explicitly sells into), it is completely absent from search: 0 of 16, 0 of 11, 0 of 11, 0 of 4. The "SLP/OT/PT" positioning is aspirational; the market sees an SLP tool. Three implications:

1. Each discipline has a different landlord. TheraPlatform owns SLP and OT; WebPT owns PT (its origin); ABA has no dominant therapy-EMR player at all. There is no single competitor to beat; there are four different SERPs with four different winners, so a one-size content plan won’t work.
2. ABA is genuine whitespace within this competitor set. Among the pediatric-therapy EMRs, nobody ranks for ABA terms; the leaders are just aggregators. (Caveat: ABA has strong dedicatedincumbents outside this set (CentralReach, Rethink, etc.), so it’s uncontested only relative to the therapy-EMR players; entering means fighting ABA-native tools, not these.)
3. This is the ICP question, made concrete. The June 1 memo asked which customer Ambiki should anchor on; the June 5 model tied NRR to focusing the core ICP. The SEO data argues the honest answer from a distribution standpoint is speech-first: it’s the only discipline where Ambiki has any toehold, the deepest product (Tenalog, articulation), and the content moat. Expanding discovery into OT/PT/ABA is a from-zero build in each, against entrenched discipline-specific leaders, a deliberate investment decision, not a freebie that comes with the current positioning.

• LinkedIn: 311 followers. For a B2B SaaS selling to practice owners and administrators, this is sub-scale: LinkedIn is where the buyer (owner/admin), not the clinician, actually is. This is the single most mismatched channel: the content engine targets clinicians on IG, while the economic buyer lives on an under-invested LinkedIn.
• Facebook + Instagram (@ambikitools), consistent with the free-tools/clinician brand; good for practitioner affinity, weak for reaching decision-makers.
• Community (r/slp, SLP Facebook groups, conference word-of-mouth), the channel where SLPs actuallytrade EMR recommendations, and where the June 1 memo already flagged Ambiki as nearly absent. No vendor owns it; it rewards authenticity over spend; it’s a natural fit for a founder-led, "built by therapists" brand.

• ASHA Corporate Partnership (Nov 2025), a credibility asset tailor-made to counter "unproven startup," and it appeared nowhere a buyer would feel it: not on the call, not on the homepage, not in the review profiles. Activating it (co-marketing, association directory presence, conference co-presence, a trust badge on the site and in the deck) is close to free credibility.
• Kevin Dias’s personal brand, founder, published author ("The Problem-First Method"), visibly active. Most competitors are faceless PE-owned suites (Ensora is literally a rollup). A founder-led narrative is a differentiation lever Ambiki isn’t fully spending, and it pairs naturally with the community channel in §5.

• seo-rankings-2026-07-09.csv, per keyword: discipline, Ambiki’s organic position, who outranks it, ad presence/bidders, and "People Also Ask" content-gap fuel.
• seo-share-of-serp-2026-07-09.csv, per competitor: how many keywords they appear on, average position, and how many keywords they outrank Ambiki.
• seo-by-discipline-2026-07-09.csv, per discipline (SLP/OT/PT/ABA/Feeding/General): Ambiki’s visibility and who leads that discipline’s SERPs (see §3.4).

The bigger, discipline-balanced sample makes the reframe undeniable. TheraPlatform appears on 52% of all category keywords at a top-4 average position; it is the category’s SEO landlord. ClinicNote and WebPT tie for the next tier (WebPT rising as PT/OT terms enter the set, its home turf). The incumbent Ambiki is built to beat, Fusion/Ensora, ranks 6th in organic presence, below four content-native challengers.

This is now a monthly share-of-SERP dashboard, the organic analog of the funnel instrumentation in the June 5 model. Re-running it each month tracks whether the move-#1 content investment is closing the gap. To refresh:

• Site map: Firecrawl /map of ambiki.com, 4,222 URLs; section breakdown in §3.1. robots.txt (crawl-delay, disallowed directories) in §3.3.
• SERPs (manual):Google results for "best EMR for speech therapy 2026," "Fusion Web Clinic alternative," "speech therapy practice management software": competitor/aggregator dominance per §3.2.
• Content: ambiki.com/blog (42 posts; discipline-tagged; some commercial listicles).
• Reviews: Capterra, Ambiki 4.9★/14; Fusion/Ensora 4.3★/707.
• Social: LinkedIn (Ambiki 311 followers; Kevin Dias founder profile), Facebook, Instagram (@ambikitools).
• Competitive scale: Ensora Health, 200,000+ providers, 28,000+ practices, Fusion 23,000+ therapists (ensorahealth.com). SPRY listicle dominance on buyer-intent terms (sprypt.com).
• Companion docs:July 9 secret-shop & GTM report; June 1 commercial-motion memo; June 5 KPI & forecast model. Paid creative in ambiki-ads-library/.
• Structured rank data: serper_seo_rank_tracker.py (§10) via SERPER_API_KEY, 134 keywords, three CSVs.